<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Dipyridamole</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00975</strong>&#160; (APRD00360)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From <span class="caps">AMA</span> Drug Evaluations Annual, 1994, p752)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00975/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00975/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00975.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00975.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00975.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00975.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00975.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00975">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Dipyridamine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Dipyudamine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Dypyridamol</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Agilease</td><td>lsei</td></tr><tr><td>Cardoxin</td><td>Rafa</td></tr><tr><td>Cleridium 150</td><td>Millot</td></tr><tr><td>Curantyl</td><td>Arzneimittelwerk</td></tr><tr><td>Persantin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Persantine</td><td>Boehringer Ingelheim</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Aggrenox</td><td>Aspirin + dipyridamole</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/platelet-aggregation-inhibitors">Platelet Aggregation Inhibitors</a></li>
<li><a href="/mesh/phosphodiesterase-inhibitors">Phosphodiesterase Inhibitors</a></li>
<li><a href="/mesh/vasodilator-agents">Vasodilator Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>58-32-2</td></tr><tr><th>Weight</th><td>Average: 504.6256<br>Monoisotopic: 504.317251808</td></tr><tr><th>Chemical Formula</th><td>C<sub>24</sub>H<sub>40</sub>N<sub>8</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>IZEKFCXSFNUWAM-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-({6-[bis(2-hydroxyethyl)amino]-4,8-bis(piperidin-1-yl)pyrimido[5,4-d][1,3]diazin-2-yl}(2-hydroxyethyl)amino)ethan-1-ol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">OCCN(CCO)C1=NC2=C(N=C(N=C2N2CCCCC2)N(CCO)CCO)C(=N1)N1CCCCC1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Diazines</td></tr><tr><th>Subclass</th><td>Pyrimidines and Pyrimidine Derivatives</td></tr><tr><th>Direct parent</th><td>Aminopyrimidines and Derivatives</td></tr><tr><th>Alternative parents</th><td>Piperidines; Polyols; Tertiary Amines; Polyamines; Primary Alcohols</td></tr><tr><th>Substituents</th><td>piperidine; tertiary amine; polyol; primary alcohol; polyamine; amine; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the aminopyrimidines and derivatives. These are organic compounds containing an amino group attached to a pyrimidine ring. Aminopyrimidines play an important role in biological processes, since the pyrimidine ring is present in several vitamins, nucleic acids, and coenzymes.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.</td></tr><tr><th>Pharmacodynamics</th><td>Dipyridamole, a non-nitrate coronary vasodilator that also inhibits platelet aggregation, is combined with other anticoagulant drugs, such as warfarin, to prevent thrombosis in patients with valvular or vascular disorders. Dipyridamole is also used in myocardial perfusion imaging, as an antiplatelet agent, and in combination with aspirin for stroke prophylaxis.</td></tr><tr><th>Mechanism of action</th><td>Dipyridamole likely inhibits both adenosine deaminase and phosphodiesterase, preventing the degradation of cAMP, an inhibitor of platelet function. This elevation in cAMP blocks the release of arachidonic acid from membrane phospholipids and reduces thromboxane A2 activity. Dipyridamole also directly stimulates the release of prostacyclin, which induces adenylate cyclase activity, thereby raising the intraplatelet concentration of cAMP and further inhibiting platelet aggregation.</td></tr><tr><th>Absorption</th><td>70%</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>1 to 2.5 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>99%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>hepatic</p></td></tr><tr><th>Route of elimination</th><td>Dipyridamole is metabolized in the liver to the glucuronic acid conjugate and excreted with the bile.</td></tr><tr><th>Half life</th><td>40 minutes</td></tr><tr><th>Clearance</th><td><ul>
	<li>2.3-3.5 mL/min/kg</li>
</ul></td></tr><tr><th>Toxicity</th><td>Hypotension, if it occurs, is likely to be of short duration, but a vasopressor drug may be used if necessary. The oral LD<sub>50</sub> in rats is greater than 6,000 mg/kg while in the dogs, the oral LD<sub>50</sub> is approximately 400 mg/kg. LD<sub>50</sub>=8.4g/kg (orally in rat)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Dipyridamole (Antiplatelet) Action Pathway</td><td>Drug action</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9917</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.6246</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7261</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7696</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5321</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8383</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.615</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8345</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.6825</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6849</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.8045</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.7201</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.957</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.6789</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7806</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7009
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8884
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.988
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1167 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Strong inhibitor 
        </td>
        <td>
            0.5271
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.633
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>App pharmaceuticals llc</li>
<li>Baxter healthcare corp anesthesia and critical care</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Claris lifesciences ltd</li>
<li>Hospira inc</li>
<li>Teva parenteral medicines inc</li>
<li>Boehringer ingelheim pharmaceuticals inc</li>
<li>Actavis totowa llc</li>
<li>Barr laboratories inc</li>
<li>Glenmark generics inc usa</li>
<li>Impax laboratories inc</li>
<li>Lannett holdings inc</li>
<li>Murty pharmaceuticals inc</li>
<li>Purepac pharmaceutical co</li>
<li>Sandoz inc</li>
<li>Watson laboratories inc</li>
<li>Zydus pharmaceuticals usa inc</li>
<li>Boehringer Ingelheim Pharmaceuticals, Inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li>Avkare Incorporated</li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.boehringer-ingelheim.com">Boehringer Ingelheim Ltd.</a></li>
<li>Cadila Healthcare Ltd.</li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Direct Dispensing Inc.</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.giv.com">General Injectables and Vaccines Inc.</a></li>
<li><a href="http://www.glenmark-generics.com">Glenmark Generics Ltd.</a></li>
<li><a href="http://www.globalphar.com">Global Pharmaceuticals</a></li>
<li><a href="http://www.ghc.org">Group Health Cooperative</a></li>
<li><a href="http://www.hhlabs.com">H and H Laboratories</a></li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.impaxlabs.com">Impax Laboratories Inc.</a></li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.lannett.com">Lannett Co. Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mallinckrodt.com">Mallinckrodt Inc.</a></li>
<li><a href="http://www.meadjohnson.com">Mead Johnson and Co.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mpirx.com">Murty Pharmaceuticals Inc.</a></li>
<li>Novex Pharma</li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.worldoftest.com">Qualitest</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.risingpharma.com">Rising Pharmaceuticals</a></li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li>Sicor Pharmaceuticals</li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.spectrumpharm.com">Spectrum Pharmaceuticals</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.zydususa.com">Zydus Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Liquid</td><td>Intravenous</td><td></td></tr><tr><td>Solution</td><td>Intravenous</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00640">Adenosine</a></td><td>Dipyridamole may increase the effect/toxicity of adenosine.</td></tr><tr><td><a href="/drugs/DB01073">Fludarabine</a></td><td>Dipyridamole may decrease the effect of fludarabine.</td></tr><tr><td><a href="/drugs/DB01381">Ginkgo biloba</a></td><td>Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB06213">Regadenoson</a></td><td>Dipyridamole may change the effects of regadenoson. When possible, withhold dipyridamole for at least two days prior to regadenoson administration. </td></tr><tr><td><a href="/drugs/DB01030">Topotecan</a></td><td>The p-glycoprotein inhibitor, Dipyridamole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>The prostacyclin analogue, Treprostinil, increases the risk of bleeding when combined with the antiplatelet agent, Dipyridamole. Monitor for increased bleeding during concomitant thearpy. Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Coffee and tea can decrease the effect of dipyridamole.</li>
<li>Take with food to reduce irritation.</li></ul></td></tr></tbody></table>